REG - BkofA Merrill Lynch Horizon Therapeutics - 20230912_HORIZON THERAPEUTICS PLC_38.5(b)_IE_MLPFS

AmgenAnnouncement

13/09/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230913:nRSM3336Ma&default-theme=true

RNS Number : 3336M  Bank of America Merrill Lynch  13 September 2023

FORM 8.2

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.2 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH

THEM FOR NON-DISCRETIONARY CLIENTS

 

 1.  KEY INFORMATION

 Name of entity dealing                     MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
 Company dealt in                           HORIZON THERAPEUTICS PLC
 Class of relevant security to which the    Common - IE00BQPVQZ61

dealings being disclosed relate (Note 1)
 Date of dealing                            12/09/2023

 

 2.  DEALINGS (Note 2)

 (a)          Purchases and sales
     Purchase/sale     Number of relevant securities  Price per unit(Note 3)
     Purchase          10                             115.289 USD
     Purchase          20                             115.415 USD
     Purchase          50                             115.44 USD

 

 Purchase/sale  Number of relevant securities  Price per unit(Note 3)
 Sale           25                             115.225 USD
 Sale           350                            115.324 USD
 Sale           2,951                          115.4 USD
 Sale           52                             115.41 USD
 Sale           50                             115.415 USD
 Sale           100                            115.42 USD
 Sale           54                             115.431 USD
 Sale           1                              115.44 USD
 Sale           560                            115.45 USD
 Sale           100                            115.465 USD

 

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction  Number of relevant securities  Price per unit

e.g. CFD
(Note 4)              (Note 5)
(Note 3)
 N/A            N/A                    N/A                            N/A

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 5)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 3)
 Put Option                      Purchasing                                  15,000                                                     115 USD         AMERICAN                           15/09/2023   0.15 USD

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 3)
 N/A                N/A                   N/A

 

 

 Date of disclosure                                       13/09/2023
 Contact name                                             Frank Lui
 Telephone number                                         +44207 996 6418
 Name of offeree/offeror with                             AMGEN INC

which acting in concert
 Specify category and nature of acting in concert status  Advisor to - AMGEN INC

Notes

1.   See the definition of "relevant securities" in Rule 2.1 of Part A of
the Rules.

2.   See the definition of "dealing" in Rule 2.1 of Part A of the Rules.

3.   For all prices and other monetary amounts, the currency must be stated.

4.   If a long position has been increased or decreased as a result of the
dealing, write "increased long" or "decreased long" respectively. If a short
position has been increased or decreased as a result of the dealing, write
"increased short" or "decreased short" respectively. If the dealing has not
resulted in a long or short position being increased or reduced, give details
of the variation or other dealing.

5.   See Rule 2.6(d) of Part A of the Rules.

For full details of disclosure requirements, see Rule 8 of the

Rules. If in doubt, consult the Panel.

 

References in these notes to "the Rules" are to the Irish Takeover

Panel Act, 1997, Takeover Rules, 2013.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEEAENDFFKDEFA